Our Program
Bayer has joined forces with world-class academic institutions and other pharma companies as part of the Structural Genomics Consortium (SGC):
In an Open Science effort we identify chemical probes for novel drug discovery targets and make them openly available for academic labs who can use these probes without any restrictions to study the disease relevance of such novel targets.
This joint effort is for the benefit of patients as high-quality science forms the basis for the next generation of therapeutics. The program is also part of the European IMI project EUbOPEN.
Your order
can be placed through
Our Offer
A set of well-characterized compounds (with corresponding negative probe). Browse the list below!


Probe Name:
BAY-3827
Negative Pair:
BAY-974
C. Lemos et al. The Potent AMPK Inhibitor BAY-3827 Shows Strong
Efficacy in Androgen-dependent Prostate Cancer Models. Cell. Oncol.
2021, 44, 581–594.
C. Lemos et al. BAY-3827, A Selective Inhibitor of AMPK for the Evaluation of the Role of AMPK in MYC-dependent Tumors. AACR poster 2018.

Probe Name:
BAY-850
Negative Pair:
BAY-460
A. E. Fernández-Montalván et al. Isoform-Selective ATAD2 Chemical
Probe with Novel Chemical Structure and Unusual Mode of Action. ACS
Chem. Biol. 2017, 12, 2730–2736.
I. Hartung et al. Probing the Cancer Epigenome – Empowering Target
Validation by Open Innovation. AACR poster 2017.


Probe Name:
BAY-299
Negative Pair:
BAY-364
L. Bouché et al. Benzoisoquinolinediones as Potent and Selective
Inhibitors of BRPF2 and TAF1/TAF1L Bromodomains. J. Med. Chem.
2017, 60, 4002–4022.
I. Hartung et al. Probing the Cancer Epigenome – Empowering Target
Validation by Open Innovation. AACR poster 2017.








Probe Name:
BAY-678
Negative Pair:
BAY-677
F. von Nussbaum et al. Freezing the Bioactive Conformation to
Boost Potency: The Identification of BAY 85-8501, a Selective and
Potent Inhibitor of Human Neutrophil Elastase for Pulmonary
Diseases. Chem. Med. Chem. 2015, 10, 1163–1173.
F. von Nussbaum et al. Neutrophil Elastase Inhibitors for the
Treatment of (Cardio) pulmonary Diseases: Into Clinical Testing
with Pre-adaptive Pharmacophores. Bioorg. Med. Chem. Lett.
2015, 25, 4370–4381.



Probe Name:
BAY-707
Negative Pair:
BAY-604
F. Rahm et al. Creation of a Novel Class of Potent and Selective
MutT Homologue 1 (MTH1) Inhibitors Using Fragment-Based
Screening and Structure-Based Drug Design. J. Med. Chem. 2018,
61, 2533–2551.
M. Ellermann et al. Novel Class of Potent and Cellularly Active
Inhibitors Devalidates MTH1 as Broad-Spectrum Cancer Target
ACS. Chem. Biol. 2017, 12, 1986–1992.






Probe Name:
BAY-598
Negative Pair:
BAY-369
E. Eggert et al. Discovery and Characterization of a Highly Potent
and Selective Aminopyrazoline-Based in Vivo Probe (BAY-598) for
the Protein Lysine Methyltransferase SMYD2. J. Med. Chem. 2016,
59, 4578–4600.
I. Hartung et al. Probing the Cancer Epigenome – Empowering Target
Validation by Open Innovation. AACR poster 2017.

Probe Name:
BAY-6035
Negative Pair:
BAY-444
S. Gradl et al. Discovery of the SMYD3 Inhibitor BAY-6035 Using
Thermal Shift Assay (TSA)-Based High-Throughput Screening. SLAS
Discov. 2021, 26, 947–960.
S. Gradl et al. Discovery and characterization of BAY-6035, a novel
benzodiazepine-based SMYD3 inhibitor. AACR poster 2018.




